Jefferies Initiates Buy Rating on Rocket Pharmaceuticals, Citing Promising Gene Therapies
Jefferies initiates Buy rating on Rocket Pharmaceuticals (RCKT) with a $29 price target, citing promising gene therapies, especially for Danon disease. Positive Phase II trial results for RP-A501 could double RCKT’s stock price, offering a compelling risk/reward profile.